Faculty introduction and disclosures

Overview of Nasopharyngeal Carcinoma Epidemiology and global distribution  Pathophysiology  Prognostic considerations and risk factors for distant metastasis  Burden of disease (localized vs metastatic)

Treatment of Advanced Nasopharyngeal Carcinoma Goals of therapy (palliation, improved failure-free and overall survival)  Treatment considerations, including recent guideline-based approaches  Combination chemotherapy  Gemcitabine/cisplatin  Alternative options  Addition of first-line immunotherapy  Immunotherapy for recurrent or metastatic disease  Immunotherapy for high tumor mutational burden  Extrapolation of data for anti-PD-1 therapies  Patient-specific factors to consider when individualizing therapy, including previous therapy (if recurrent disease)  Investigational agents  Novel agents  Novel combinations  Management of symptoms, adverse effects, and complications during disease course  Multidisciplinary team approach:  Structure, role, and impact  Considerations for RT in advanced disease   Putting it all together: patient case(s)

Summary, conclusions, and best practice recap

By the end of the session the participant will be able to:

• Recall the new and emerging treatment options for advanced NPC and how to assess risk factors, prognosis, treatment response, and toxicity.
• Describe the symptomatic and treatment-related adverse effects associated with metastatic NPC and how to manage them.
• Define the role and importance of a multidisciplinary approach in caring for patients with advanced NPC.
• Formulate a treatment plan for a patient with metastatic NPC.

ACCME Activity #202633471

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Disclosure of Faculty: Deborah J.L. Wong, MD, HS Associate Clinical Professor, Medicine, David Geffen School of Medicine at UCLA, has received financial compensation from Merck and Regeneron for consulting and AstraZeneca/MedImmune, Bicara Therapeutics, Bristol Myers Squibb, Checkmate Pharmaceuticals, Flamingo Pharma, Genentech, Gilead Sciences, Hookipa Biotech, invoX Pharma, Kura Oncology, Eli Lilly, Merck, Pfizer, Regeneron, TopAlliance BioSciences for grants/research support.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Faculty WILL NOT discuss off-label uses of a commercial product.

All relevant financial relationships have been mitigated.

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from Coherus BioSciences. 

• Read the learning objectives above
• Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
• View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
• Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
• Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

*Required to view Printable PDF Version